Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.
Awakn Life Sciences has announced that Awakn Clinics Trondheim is now open and that it has initiated a feasibility study of MDMA leveraging Catalent’s proprietary Zydis...
Optimi Health has submitted an application to carry out a Phase I clinical trial investigating the safety of the combinatory use of psilocybin and MDMA in...
In a groundbreaking development, Australia is to reclassify psilocybin and MDMA to enable prescribing by authorised psychiatrists.
Results from MAPS PBC’s study have demonstrated a biological correlation between a reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders.
The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
MAPS has announced further developments in its Phase 3 study of MDMA-assisted therapy for the treatment of PTSD.
Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.